Although the use of tamoxifen significantly improves the survival of women with early-stage breast cancer [7], unfortunately, not all ERα-positive tumors respond to this therapy (de novo resistance), and almost all patients with metastatic ERα-positive disease eventually develop endocrine resistance (acquired resistance) [7,8,9]. This evidence concerns the gene ESR1 and breast carcinoma.